UroGen Pharma's Chief Medical Officer Mark Schoenberg sold 10,000 ordinary shares for $400,000 on July 9, 2026, according to an SEC filing. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted in August 2025 and represents the final transaction of that plan. Schoenberg continues to hold 119,763 shares directly, valued at approximately $4.82 million based on the $40.23 closing price that day. The transaction occurred with UroGen's market capitalization at $2.0 billion, following a 191% stock surge over the prior year, and as the company reported trailing 12-month revenue of $140.5 million and a net loss of $133.2 million. The company's first-quarter revenue jumped 152% to $51 million, driven by the launch of its new bladder cancer therapy Zusduri, which contributed $29.2 million after a permanent insurance billing code took effect.
UroGen Pharma LtdCMO sold $400k stock under pre-planned 10b5-1 plan; no insider concern, but sale follows 191% run-up.